significantTreatment update

Benralizumab (anti-IL-5Rα) FDA-approved for CRSwNP (2024)

Chronic Rhinosinusitis with Nasal Polyps →

Summary

OSTRO trial led to FDA approval of benralizumab for CRSwNP in 2024, making it the fourth approved biologic. Unique ADCC mechanism achieves near-complete eosinophil depletion.

Related treatments

BenralizumabAnti–IL-5Rα monoclonal antibody (ADCC-mediated eosinophil depletion)
1st-line biologic lineNear-complete eosinophil depletion

More from Chronic Rhinosinusitis with Nasal Polyps

incrementalNew research

Alarmin-targeting biologics in development for CRSwNP

significantNew research

Head-to-head biologic comparison studies beginning

ID: crswnp-update-0Type: treatment_updateImpact: significant